272 related articles for article (PubMed ID: 35309350)
1. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
[TBL] [Abstract][Full Text] [Related]
3. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
[No Abstract] [Full Text] [Related]
5. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
Yang Y; Jin G; Pang Y; Huang Y; Wang W; Zhang H; Tuo G; Wu P; Wang Z; Zhu Z
Front Pharmacol; 2020; 11():40. PubMed ID: 32116716
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
Xian F; Wu J; Zhong L; Xu G
Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
10. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
12. The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.
Liu Q; Zhang Y; Liu M; Xu R; Yi F; Wei Y; Zhu S; Zhang W
World J Surg Oncol; 2021 Oct; 19(1):298. PubMed ID: 34645484
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.
Rui M; Wang Z; Fei Z; Wu Y; Wang Y; Sun L; Shang Y; Li H
Front Pharmacol; 2022; 13():862640. PubMed ID: 35370659
[No Abstract] [Full Text] [Related]
16. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract][Full Text] [Related]
17. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
Yeo BSY; Song HJJMD; Soong YL; Chua MLK; Ang MK; Lim DWT; See A; Lim CM
Oral Oncol; 2023 Jan; 136():106242. PubMed ID: 36413976
[TBL] [Abstract][Full Text] [Related]
19. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
Wang Y; Xun Z; Yang X; Wang Y; Wang S; Xue J; Zhang N; Yang X; Lu Z; Zhou J; Zhou K; Sang X; Zhao H
Am J Cancer Res; 2023; 13(3):1026-1037. PubMed ID: 37034211
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]